戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e physiological index (CPI) in patients with pulmonary sarcoidosis.
2  staging system for determining prognosis in pulmonary sarcoidosis.
3  their body surface area and had evidence of pulmonary sarcoidosis.
4 y was conducted in 138 patients with chronic pulmonary sarcoidosis.
5 ays linked to development and progression of pulmonary sarcoidosis.
6  with prednisone as first-line treatment for pulmonary sarcoidosis.
7  more than 60% of deaths are due to advanced pulmonary sarcoidosis.
8 ter (PM(2.5)) with lung function outcomes in pulmonary sarcoidosis.
9 ant contributor to spontaneous resolution of pulmonary sarcoidosis.
10 D8(+) T cells from patients with progressive pulmonary sarcoidosis and end-stage disease.
11 ar lavage cells and fluid from patients with pulmonary sarcoidosis and idiopathic pulmonary fibrosis
12        Overall, 70% of patients had stage IV pulmonary sarcoidosis, and 77% had functional class III/
13 olves the lung and is described as "advanced pulmonary sarcoidosis" (APS), which includes advanced pu
14            Extrinsic allergic alveolitis and pulmonary sarcoidosis are granulomatous diseases of the
15 gh optimal doses of oral glucocorticoids for pulmonary sarcoidosis are unknown, oral prednisone typic
16                                 He diagnosed pulmonary sarcoidosis, because of elevation of serum ang
17  recommended as the first-line treatment for pulmonary sarcoidosis but is associated with many side e
18                                              Pulmonary sarcoidosis can be asymptomatic or result in i
19  be the predominant producer of IFN-gamma in pulmonary sarcoidosis, challenging the Th1 paradigm of p
20                             He was diagnosed pulmonary sarcoidosis complicated with bronchial asthma.
21          Up to 70% of patients with advanced pulmonary sarcoidosis develop precapillary pulmonary hyp
22               More than 10% of patients with pulmonary sarcoidosis develop progressive disease and mo
23   The test cohort included 251 patients with pulmonary sarcoidosis in the study referred to the Sarco
24                             In patients with pulmonary sarcoidosis, initial treatment with methotrexa
25                                              Pulmonary sarcoidosis is classically defined by T-helper
26                                   Rationale: Pulmonary sarcoidosis is generally presumed to be a T-he
27                                 Mortality in pulmonary sarcoidosis is highly variable and a reliable
28                                    A case of pulmonary sarcoidosis is presented in which cytologic an
29 clear prognostic separation of patients with pulmonary sarcoidosis is provided by a simple staging sy
30 ransplant recipient with a remote history of pulmonary sarcoidosis on chronic immunosuppression who d
31 osis), and stage III/IV (confirmed fibrosis) pulmonary sarcoidosis patients, and fibroblast strains i
32 arcoidosis, which accounts for 10% to 20% of pulmonary sarcoidosis patients.
33 lood genome-wide transcriptional profiles in pulmonary sarcoidosis, pulmonary tuberculosis, to commun
34 1 of 304 consecutive patients with suspected pulmonary sarcoidosis (stage I/II) in whom tissue confir
35                          Among patients with pulmonary sarcoidosis, the rate of spontaneous remission
36 hods, we studied patients with stages II-III pulmonary sarcoidosis to determine (1) whether the modif
37     Among patients with suspected stage I/II pulmonary sarcoidosis undergoing tissue confirmation, th
38              An individual with a history of pulmonary sarcoidosis was referred for evaluation and tr
39  nonsmoking adults with specialist-diagnosed pulmonary sarcoidosis were used.
40 en almost exclusively in those with fibrotic pulmonary sarcoidosis, which accounts for 10% to 20% of
41 noninferiority trial involving patients with pulmonary sarcoidosis who had not previously received tr